Unlike many other cancers, most pancreatic tumors are rock hard.
“That’s one reason why pancreatic cancer is one of the most lethal types of cancer,” says Kenneth Olive, PhD, associate professor of medicine and pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons and a pancreatic cancer researcher at the Herbert Irving Comprehensive Cancer Center.
“Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield,” says Olive, whose previous research first uncovered how the stroma makes it difficult for chemotherapy drugs to reach malignant cells. “As a result, most chemotherapy drugs can’t build up to the levels needed to be effective.”
To Olive, that suggests, paradoxically, a longer-lived—but less toxic—drug may work better.
“For a pancreatic cancer drug to be effective, it needs to stick around long enough to seep past the stroma and accumulate in the tumor. But if it is going to persist for a long time in the blood, it can’t be as toxic to the rest of the body,” he says.
Pancreatic Ductal Adenocarcinoma
Despite some recent improvements in pancreatic cancer treatment, the five-year survival rate for individuals with this disease is only around 9%.
Testing a New Drug Combination
Olive’s latest research, which was led by Jaime Eberle-Singh, PhD, while she was a graduate student at Columbia, may have identified a good candidate. The drug, an experimental compound called PTC596 that had shown antitumor activity in mouse and human pancreatic cancer cells, seemed to have the right qualities: PTC596 has a durable half-life (most cancer drugs have a half-life of a few minutes to hours) and can evade a pump that many cancer cells use to expel drugs. “This means that any amount of drug that makes it past the barrier can target the malignant cells,” says Olive.
Based on those studies, Olive, Eberle-Singh, and their collaborators tested PTC596 in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy.
The mice that were treated with the two-drug combination lived three times longer than those treated with only a single standard agent. “This result was exciting because it’s exceedingly rare for any treatment to extend survival in this gold-standard mouse model,” Olive says.
They also tested PTC596 in combination with gemcitabine and another drug commonly used to treat pancreatic cancer, nab-paclitaxel, using human pancreatic tumors grown in mice. This combination further enhanced efficacy, making the tumors shrink outright.
“Based on the drug’s safety profile and our own findings, there’s a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer,” says Olive.
Olive’s team also discovered that PTC596 blocks the formation of microtubules—a network of proteins involved in cell division and transport of nutrients within the cell. He demonstrated that PTC596 may act synergistically with nab-paclitaxel, another microtubule-binding agent.
“Combining different microtubule inhibitors has the potential to play an important role in the future of oncology, as there are many agents that each impact microtubules in different ways that could produce synergy,” Olive says.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- New drug combo may improve pancreatic cancer therapy on November 18, 2019 at 3:26 pm
A new study by scientists at Sanford Burnham Prebys Medical Discovery Institute have discovered a combination of two cancer-fighting drugs that successfully worked on pancreatic tumor in mice, ...
- Mouse study prompts clinical trial of new pancreatic cancer therapy on November 18, 2019 at 1:11 pm
They are meeting with oncologists at Oregon Health and Science University to plan the trial. A cancer researcher not involved in the study said its findings make a clinical trial worth performing in ...
- One-two punch drug combination offers hope for pancreatic cancer therapy on November 18, 2019 at 8:03 am
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice—supporting the immediate evaluation of ...
- David Gibson, owner of Gibson’s Bakery in Oberlin, dies after fight with pancreatic cancer on November 17, 2019 at 12:36 pm
OBERLIN, Ohio – David Gibson, the owner of Gibson’s Bakery of Oberlin, died Saturday at his home after a months-long fight with pancreatic cancer. The news of his death was shared on the family ...
- David Gibson of Oberlin's Gibson's Bakery passes away after battle with pancreatic cancer on November 16, 2019 at 3:02 pm
Gibson's Bakery announced on its Facebook page that David Gibson died on Saturday morning at home after a battle with pancreatic cancer. In June of this year, David Gibson, his son Allyn Gibson, and ...
- November is Pancreatic Cancer Awareness Month on November 14, 2019 at 4:04 pm
NOVEMBER IS PANCREATIC CANCER AWARENESS MONTH. AND OUR LOCAL PANCREATIC CANCER ACTION NETWORK HAS SEVERAL EVENTS PLANNED. I’M JOINED NOW BY HOLLY IGNATOWSKI AND SURVIVOR TIM NENNIG. THANK YOU FOR ...
- 'Jeopardy!' contestants ask fans to play along for pancreatic cancer research on November 14, 2019 at 2:30 pm
Jeopardy!' contestants ask fans to play along for pancreatic cancer research In honor of Alex Trebek and Larry Martin, "Jeopardy!" contestants are asking fans to play along this week and donate to ...
- Farm to Table dinner raises funds for Aiken's pancreatic cancer patients on November 14, 2019 at 2:26 pm
Farm to Table is a bustling event that grows larger every year and serves as one of the biggest fundraisers for pancreatic cancer patients in Aiken County; however, the event – which packed Newberry ...
- Play along with 'Jeopardy!' champs to raise money for pancreatic cancer research on November 14, 2019 at 1:49 pm
Three of Jeopardy's most decorated champions will battle on Thursday and Friday for this year's Tournament of Champions, and they are asking fans of the show to help raise money for pancreatic cancer ...
- First Texas 5k walk to raise funds for pancreatic cancer set for Woodlands on Saturday on November 14, 2019 at 12:54 pm
June 2019 United in Purple 5k walk in Lake Tye in Monroe, WA. June 2019 The first United in Purple 5k walk in Texas for pancreatic cancer is set for Creekside Park in The Woodlands on Saturday. After ...
via Bing News